

FOR IMMEDIATE RELEASE

For More Information Contact:

Michael Schmainda
Imaging Biometrics, LLC
(262) 439-8252 • mike@imagingbiometrics.com



IB Neuro Proves Superior in Head-to-Head Competition

For Immediate Release

May 6, 2015

Elm Grove, WI – Imaging Biometrics®, LLC (IB), a biotechnology company specializing in the development of software solutions for advanced visualization and analytics, proudly announces the results of a comparison study presented at this year’s American Society of Neuroradiology (ASNR) meeting in Chicago. The study compared IB Neuro, IB’s magnetic resonance imaging (MRI) dynamic susceptibility contrast (DSC) perfusion product, to Nordic Neuro Lab’s NordiciCE (Bergen, Norway). The results showed that IB Neuro outperformed NordiciCE in terms of accuracy, its ability to distinguish tumor from treatment effects, and its correlation between relative cerebral blood volume (rCBV) and histologic microvessel volume.

The study, “Impact of software modeling on the accuracy of perfusion MRI in glioma,” aimed to assess whether software modeling affects the accuracy of rCBV output. The results have been accepted for publication in the American Journal of Neuroradiology (AJNR) and demonstrate that software modeling does affect results as IB Neuro outperformed NordiciCE in all areas in which they were compared.


DSC derived rCBV is widely accepted as a primary imaging biomarker for brain tumors. Its clinical application ranges from grading tumors and guiding surgical biopsies to monitoring therapeutic response. “The need to accurately quantify changes in brain tumor patients is becoming increasingly difficult due to the challenging side effects of newer therapies and cancer fighting agents.” said Michael Schmainda, President of IB. “The true test of accuracy is the correlation of tissue samples with the software output. MRI has many sources of inherent variability and, from a post-processing perspective, we are proud that the results validate the accuracy of our product. This study, along with previous studies recently published in *Neuro Oncology*, may pave the way for reaching consensus on one perfusion approach. This would remove a wide-range of variability for patients, multi-center trials, scientists, and even drug development companies. In fact, the earlier we can provide drug development companies with more accurate information during their development cycles, the faster promising cancer-fighting agents can be made available for patients,” Schmainda added.

IB continues to enhance IB Neuro with major improvements currently in development. Along with an exclusively licensed algorithm, termed standardization, that enables consistent rCBV analysis across time

FOR IMMEDIATE RELEASE

For More Information Contact:

Michael Schmainda
Imaging Biometrics, LLC
(262) 439-8252 • mike@imagingbiometrics.com



and MRI platforms, IB will soon introduce its patented “dual-echo” methodology in IB Neuro v2.0. This version of IB Neuro will allow for both DSC and DCE parameters to be generated using a single MR acquisition sequence and a single dose of gadolinium contrast agent.

About Imaging Biometrics™ LLC

Imaging Biometrics develops and provides visualization and analytical solutions enabling clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualization software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, LLC, visit www.imagingbiometrics.com.